Amedisys Home Health and Hospice Care (AMED) Reaches New 1-Year High and Low at $74.19

Amedisys Home Health and Hospice Care (NASDAQ:AMED)’s share price hit a new 52-week high and low during trading on Thursday . The stock traded as low as $74.19 and last traded at $74.46, with a volume of 9696 shares trading hands. The stock had previously closed at $72.36.

AMED has been the topic of several analyst reports. BidaskClub upgraded Amedisys Home Health and Hospice Care from a “buy” rating to a “strong-buy” rating in a report on Friday, April 6th. Royal Bank of Canada upgraded Amedisys Home Health and Hospice Care from a “sector perform” rating to an “outperform” rating in a report on Monday, March 19th. Zacks Investment Research upgraded Amedisys Home Health and Hospice Care from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a report on Tuesday, March 6th. Finally, Robert W. Baird set a $66.00 price target on Amedisys Home Health and Hospice Care and gave the company a “hold” rating in a report on Thursday, March 1st. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Amedisys Home Health and Hospice Care currently has a consensus rating of “Buy” and an average price target of $66.90.

The company has a debt-to-equity ratio of 0.14, a current ratio of 1.63 and a quick ratio of 1.63. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of 33.67, a P/E/G ratio of 1.36 and a beta of 0.66.

Amedisys Home Health and Hospice Care (NASDAQ:AMED) last posted its quarterly earnings data on Monday, May 7th. The health services provider reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.12. Amedisys Home Health and Hospice Care had a return on equity of 16.83% and a net margin of 2.71%. The company had revenue of $399.30 million during the quarter, compared to analysts’ expectations of $395.38 million. During the same period in the prior year, the business earned $0.47 earnings per share. Amedisys Home Health and Hospice Care’s revenue for the quarter was up 9.5% compared to the same quarter last year. equities analysts anticipate that Amedisys Home Health and Hospice Care will post 3.03 EPS for the current fiscal year.

In other news, insider Michael Paul North sold 11,000 shares of the stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $71.52, for a total value of $786,720.00. Following the completion of the sale, the insider now directly owns 15,206 shares of the company’s stock, valued at $1,087,533.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of AMED. Schwab Charles Investment Management Inc. lifted its position in Amedisys Home Health and Hospice Care by 1.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 176,363 shares of the health services provider’s stock worth $9,297,000 after purchasing an additional 3,315 shares during the period. Acadian Asset Management LLC lifted its position in Amedisys Home Health and Hospice Care by 47.3% in the fourth quarter. Acadian Asset Management LLC now owns 51,596 shares of the health services provider’s stock worth $2,719,000 after purchasing an additional 16,563 shares during the period. Fox Run Management L.L.C. bought a new position in Amedisys Home Health and Hospice Care in the fourth quarter worth $269,000. Mitsubishi UFJ Asset Management UK Ltd. lifted its position in Amedisys Home Health and Hospice Care by 15.6% in the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 22,200 shares of the health services provider’s stock worth $1,170,000 after purchasing an additional 3,000 shares during the period. Finally, Bowling Portfolio Management LLC bought a new position in Amedisys Home Health and Hospice Care in the fourth quarter worth $2,146,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

About Amedisys Home Health and Hospice Care

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Receive News & Ratings for Amedisys Home Health and Hospice Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Home Health and Hospice Care and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit